Kraig Biocraft Laboratories Launches Spider Silk Production at Recently Completed Higher Capacity Facility
Kraig Biocraft Laboratories (OTCQB: KBLB) has launched its first production cycle for BAM-1 parental strains at a newly established production center. The facility is eight times larger than the previous one and has the capacity to support the production of 25 metric tons of spider silk per year when fully utilized. This expansion marks a significant milestone in the company's growth and its commitment to transforming the textile industry.
The new production center is strategically located to optimize operations and provide easy access to supporting infrastructure. It was built to address production space requirements for 2025 and create a foundation for future expansion. Kraig Labs anticipates building additional production capacity in 2025 to bring more silk production online for 2026.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha lanciato il suo primo ciclo di produzione per le ceppi parentali BAM-1 in un nuovo centro di produzione. La struttura è otto volte più grande rispetto a quella precedente e ha la capacità di supportare la produzione di 25 tonnellate metriche di seta di ragno all'anno quando sarà pienamente operativa. Questa espansione rappresenta un traguardo significativo nella crescita dell'azienda e nel suo impegno a trasformare l'industria tessile.
Il nuovo centro di produzione è posizionato strategicamente per ottimizzare le operazioni e fornire un accesso facile alle infrastrutture di supporto. È stato costruito per affrontare le esigenze di spazio produttivo per il 2025 e per creare una base per future espansioni. Kraig Labs prevede di costruire capacità produttiva aggiuntiva nel 2025 per aumentare la produzione di seta nel 2026.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha lanzado su primer ciclo de producción para las cepas parentales BAM-1 en un nuevo centro de producción. La instalación es ocho veces más grande que la anterior y tiene la capacidad de soportar la producción de 25 toneladas métricas de seda de araña al año cuando esté completamente operacional. Esta expansión marca un hito significativo en el crecimiento de la empresa y su compromiso de transformar la industria textil.
El nuevo centro de producción está estratégicamente ubicado para optimizar las operaciones y proporcionar un fácil acceso a la infraestructura de apoyo. Se construyó para abordar los requisitos de espacio de producción para 2025 y crear una base para futuras expansiones. Kraig Labs anticipa construir capacidad de producción adicional en 2025 para aumentar la producción de seda en 2026.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 BAM-1 부모 균주에 대한 첫 번째 생산 사이클을 시작했습니다 신설된 생산 센터에서. 이 시설은 이전 시설보다 8배 더 큽니다 연간 25미터톤의 거미줄 생산 용량을 지원할 수 있습니다. 이러한 확장은 회사 성장의 중요한 이정표로, 섬유 산업 혁신에 대한 약속을 의미합니다.
새로운 생산 센터는 운영 최적화를 위해 전략적으로 위치하고 있어 지원 인프라에 대한 접근이 용이합니다. 2025년 생산 공간 요구 사항을 해결하고 미래 확장을 위한 기반을 마련하기 위해 건설되었습니다. Kraig Labs는 2025년에 추가 생산 용량을 구축하여 2026년의 실크 생산을 늘릴 계획입니다.
Kraig Biocraft Laboratories (OTCQB: KBLB) a lancé son premier cycle de production pour les souches parentales BAM-1 dans un nouveau centre de production. L'installation est huit fois plus grande que la précédente et a la capacité de produire 25 tonnes métriques de soie d'araignée par an lorsqu'elle sera pleinement opérationnelle. Cette expansion marque une étape importante dans la croissance de l'entreprise et son engagement à transformer l'industrie textile.
Le nouveau centre de production est stratégiquement situé pour optimiser les opérations et offrir un accès facile à l'infrastructure de soutien. Il a été construit pour répondre aux besoins en matière d'espace de production pour 2025 et créer une base pour de futures expansions. Kraig Labs prévoit de construire une capacité de production supplémentaire en 2025 pour augmenter la production de soie en 2026.
Kraig Biocraft Laboratories (OTCQB: KBLB) hat seinen ersten Produktionszyklus für die BAM-1-Elterntypen in einem neu eingerichteten Produktionszentrum in Betrieb genommen. Die Anlage ist achtmal größer als die vorherige und hat die Kapazität, 25 metrische Tonnen Spinnenseide pro Jahr zu produzieren, wenn sie voll genutzt wird. Diese Erweiterung stellt einen bedeutenden Meilenstein im Wachstum des Unternehmens und sein Engagement zur Transformation der Textilindustrie dar.
Das neue Produktionszentrum ist strategisch gelegen, um den Betrieb zu optimieren und einen einfachen Zugang zur unterstützenden Infrastruktur zu ermöglichen. Es wurde gebaut, um die Anforderungen an Produktionsflächen für 2025 zu erfüllen und eine Grundlage für zukünftige Erweiterungen zu schaffen. Kraig Labs plant, im Jahr 2025 zusätzliche Produktionskapazitäten aufzubauen, um die Seidenproduktion im Jahr 2026 zu erhöhen.
- New production facility is 8 times larger than the previous one
- Capacity to produce 25 metric tons of spider silk per year when fully utilized
- Strategic location optimizes operations and provides easy access to infrastructure
- Plans for additional production capacity expansion in 2025 for 2026 output
- None.
ANN ARBOR, Mich., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), proudly announces the initiation of its first production cycle for the BAM-1 parental strains at its newly established production center. This new facility boasts a footprint eight times larger than its previous facility and, when fully utilized, has the capacity to support the production of 25 metric tons of spider silk per year. This transition to a larger facility marks a pivotal moment in the Company's growth and its commitment to transforming the textile industry.
The new production center, strategically located to optimize operations and provide easy access to supporting infrastructure, is set to accelerate the Company's capacity for high-quality, bioengineered spider silk. This production center represents a monumental leap forward in capacity, enabling Kraig Labs to meet the demand for its groundbreaking spider silk materials and solidify its leadership in bio-engineered fibers.
This facility was built to address the production space requirements for 2025 and to create a foundation for future expansion. With this proven production blueprint established, the Company anticipates building out additional production capacity in 2025 to bring additional silk production capacity online for 2026.
"We are thrilled to embark on this new chapter in Kraig Labs' journey," said Company Founder and CEO, Kim Thompson. "Launching this first production cycle at this greatly expanded facility is not only a testament to our team's dedication and hard work but also a major milestone in our mission to revolutionize material science and commercialize spider silk. Our new center will significantly enhance our production capacity, allowing us to scale up and bring our innovative spider silk technologies to a broader market."
The launch of this production cycle and the investment into the expansion of facilities underscores the Company's commitment to innovation and excellence in the field of bioengineered materials. With the expanded rearing capabilities, Kraig Labs aims to set new benchmarks in both production capacity and product quality, strengthening its position as a leader in the advanced materials sector.
As Kraig Biocraft Laboratories embarks on this exciting new phase, the Company extends its gratitude to its partners, investors, and team members for their unwavering support. The new production center is set to play a crucial role in driving the Company's growth and reinforcing its position as a trailblazer in bioengineered materials.
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the production capacity of Kraig Biocraft Laboratories' new facility?
How much larger is Kraig Biocraft Laboratories' (KBLB) new production center compared to the previous one?
When does Kraig Biocraft Laboratories (KBLB) plan to expand its production capacity further?
What spider silk strain is Kraig Biocraft Laboratories (KBLB) producing in its first production cycle at the new facility?
